摘要：

The in vitro and in vivo effects of (PGE2) and of its stable analogue, 16,16--PGE2 (dmPGE2), on myelopoiesis and on the myelopoiesis-associated immune suppressor activity of bearing metastatic variant (LLC-C3) are assessed. In vitro studies showed a reduced susceptibility of bone marrow myeloid progenitor () from LLC-C3 bearers versus normal to the -inhibitory effects of PGE2. When added to cocultures of bone marrow with LLC-C3 supernatants, PGE2 lessened the frequency of and slightly reduced the generation of bone marrow immune suppressor . In vivo studies showed that 4 daily injections of dmPGE2 into LLC-C3 -bearing caused some reduction in femoral bone marrow and had an insignificant effect on bone marrow suppressor activity. In contrast to the relative insensitivity of bone marrow of bearers to the effects of PGE2, in vitro studies showed that by spleen of bearers was readily inhibited by PGE2. Likewise, in vivo studies showed that spleen of dmPGE2-treated LLC-C3-bearing had a reduction in cellularity, , and the level of spontaneous proliferation; a reduction in suppressor activity; and an increase in blastogenesis. Thus, short-term dmPGE2 treatment of LLC-C3-bearing limited the -induced splenic myelopoiesis and reduced the associated splenic immune suppressor activity.

展开